Expanded Access to Upadacitinib
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Upadacitinib (Primary)
- Indications Crohn's disease
- Focus Expanded access; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 04 Apr 2025 Status changed from completed to recruiting.
- 02 Aug 2021 Status changed from recruiting to completed.
- 13 Nov 2019 New trial record